The top 20 global biopharmaceutical companies experienced a 5.7% decrease in combined market capitalization, dropping from $3.92 trillion to $3.70 trillion due to US drug pricing pressures and ongoing tariffs from the Trump administration.

Alnylam saw the largest market capitalization growth at 21.8%, reaching $42.5 billion, driven by the success of its RNAi therapeutic Amvuttra for ATTR-CM, with global sales reaching $310 million in Q1 2025.

Novartis reported a 7.7% increase in market capitalization in Q2 2025, bolstered by strong financial performance and blockbuster drug sales, including the acquisition of Regulus Therapeutics for $1.7 billion.

Bristol Myers Squibb faced the largest market capitalization decline at 22.9% in Q2 2025, following mixed financial performance and disappointing trial results for Cobenfy as an adjunctive therapy for schizophrenia.

Regeneron and Sanofi saw declines in market capitalization due to the failure of itepekimab to meet endpoints in a Phase III trial for chronic obstructive pulmonary disease, impacting plans for regulatory approval.

Regeneron’s market capitalization decline was also influenced by challenges with Eylea and Eylea HD sales, facing competition from VEGF inhibitors like Avastin and biosimilar Enzeevu.

Merck & Co experienced an 11.8% decline in market capitalization in Q2 2025, attributed to concerns over the performance of its Gardasil vaccine in China and a 40% drop in global sales in Q1 2025.

Biopharmaceutical companies are facing mounting challenges due to US tariff announcements and drug pricing pressures, impacting investor sentiment and market capitalization in Q2 2025. Some companies, like Alnylam and Novartis, have shown resilience amid these difficulties.

The biopharmaceutical industry is navigating challenges, with market caps falling 5.7% among the top 20 companies, as reported by Pharmaceutical Technology, a GlobalData-owned brand.

Read more at Yahoo Finance: Top 20 biopharma market caps fall 5.7% amid industry challenges